Physician profile
Herbert L Lim
NPI 1700892957
$16,534.54
in general payments reported to CMS, 2019-2025
30 companies · $5,113 in 2025
The $5,113 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,497 · 2020: $855 · 2021: $1,321 · 2022: $2,330 · 2023: $2,321 · 2024: $3,097 · 2025: $5,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,585 · Travel and Lodging: $926 · Education: $20.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,585.00 |
| Travel and Lodging | $925.61 |
| Education | $20.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,171.91 | 2019-2025 | |
| Gilead Sciences, INC. | $2,685.48 | 2019-2025 | Livdelzi, Epclusa, Vemlidy |
| Boston Scientific Corporation | $1,758.29 | 2019-2025 | Overstitch Nxt Endoscopic Suturing System, Resolution Clip, Overstitch Endoscopic Suturing System |
| Pfizer INC. | $1,608.42 | 2019-2025 | |
| Janssen Biotech, INC. | $1,007.18 | 2023-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $638.32 | 2019-2024 | Entyvio, Gattex |
| E.R. Squibb & Sons, L.L.C. | $601.02 | 2019-2025 | Opdivo |
| Madrigal Pharmaceuticals | $598.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $577.59 | 2019-2024 | Ocaliva |
| Exact Sciences Corporation | $344.84 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $237.09 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $229.61 | 2021-2024 | Givlaari |
| Medtronic, INC. | $226.67 | 2021-2023 | Gi Genius |
| Janssen Scientific Affairs, LLC | $224.47 | 2025 | Tremfya |
| Fujifilm Healthcare Americas Corporation | $204.54 | 2024 | Utaswako Afp-L3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orphalan INC | $180.23 | 2024 | Cuvrior |
| Genzyme Corporation | $147.84 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $147.03 | 2025 | Iqirvo |
| Regeneron Pharmaceuticals, INC. | $128.70 | 2023 | Dupixent |
| Exelixis INC. | $128.09 | 2019 | |
| Novo Nordisk INC | $124.89 | 2025 | |
| Ardelyx, INC. | $112.94 | 2024 | Ibsrela |
| Astrazeneca Pharmaceuticals Lp | $104.40 | 2024-2025 | Imfinzi |
| Covidien Lp | $87.42 | 2019 | |
| Ironwood Pharmaceuticals, INC | $69.52 | 2019-2020 | |
| Celgene Corporation | $52.93 | 2022-2023 | Zeposia |
| Celltrion USA INC. | $52.31 | 2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $36.83 | 2021 | |
| Mallinckrodt Hospital Products INC. | $24.69 | 2023 | Terlivaz |
| Ferring Pharmaceuticals INC. | $22.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.